# OnCo record emerald-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/emerald-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "emerald-1", "NCT03778957" ;
  schema:name "EMERALD-1"@en ;
  schema:description "The first trial to show that adding immunotherapy and an anti-VEGF drug to TACE delays progression in intermediate-stage liver cancer."@en ;
  schema:url <https://onco.cc/trials/emerald-1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03778957>, <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02551-0/abstract> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2018-11-30" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:technologies <https://onco.cc/technologies/tace/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/tace-term/> .